Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

被引：3
|
作者：
Osman, Keren [1 ]
Chari, Ajai [2 ]
Parekh, Samir Sunil [3 ]
Caro, Jessica [4 ]
Aleman, Adolfo [4 ]
Mandeli, John [4 ]
Jagannath, Sundar [5 ]
Cho, Hearn Jay [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, Bone Marrow & Stem Cell Transplantat, New York, NY 10029 USA
[2] Mt Sinai Med Ctr, New York, NY 10029 USA
[3] Montefiore Med Ctr, Albert Einstein Coll Med, Oncol, Bronx, NY 10467 USA
[4] Mt Sinai Sch Med, New York, NY USA
[5] St Vincents Comprehens Canc Ctr, New York, NY USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 03期
关键词：
D O I：
10.1016/j.bbmt.2017.12.601
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
26
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [1] Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
    Osman, Keren
    Chari, Ajai
    Parekh, Samir
    Pun, Christine
    Morgan, Gillian
    Florendo, Erika
    Chan, Elaine
    Shields, Marisa
    Strumolo, Gina
    La, Lisa
    Mandeli, John
    Geerlof, James
    Jagannath, Sundar
    Cho, Hearn Jay
    BLOOD, 2016, 128 (22)
  • [2] Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
    Osman, Keren
    Chari, Ajai
    Parekh, Samir Sunil
    Pun, Christine
    La, Lisa
    Mandeli, John
    Jagannath, Sundar
    Cho, Hearn Jay
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S133 - S134
  • [3] Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma.
    Osman, Keren
    Cho, Hearn J.
    Chari, Ajai
    Parekh, Samir S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
    Osman, Keren
    Chari, Ajai
    Parekh, Samir
    Aleman, Adolfo
    Caro, Jessica
    Morgan, Gillian
    Florendo, Erika
    Chan, Elaine
    Strumolo, Gina
    Zarychta, Katarzyna
    La, Lisa
    Mandeli, John
    Kim-Schultze, Seunghee
    Gnjatic, Sacha
    Jagannath, Sundar
    Cho, Hearn Jay
    BLOOD, 2017, 130
  • [5] Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
    Coffey, David G.
    Osman, Keren
    Aleman, Adolfo
    Bekri, Selma
    Kats, Simone
    Dhadwal, Amishi
    Catamero, Donna
    Kim-Schulze, Seunghee
    Gnjatic, Sacha
    Chari, Ajai
    Parekh, Samir
    Jagannath, Sundar
    Cho, Hearn Jay
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [6] Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Weber, Donna
    Thomas, Sheeba K.
    Wang, Michael
    Turturro, Francesco
    Qazilbash, Muzaffar H.
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday R.
    Manasanch, Elisabet E.
    Munoz, Silvia C.
    Landry, Ashley
    Mendoza, Kathleen
    Nieto, Yago
    Champlin, Richard E.
    Orlowski, Robert Z.
    BLOOD, 2015, 126 (23)
  • [7] Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Thomas, Sheeba K.
    Shah, Jatin J.
    Lee, Hans C.
    Manasanch, Elisabet E.
    Weber, Donna M.
    Patel, Krina K.
    Feng, Lei
    Amini, Behrang
    Morphey, Ashley
    Crumpton, Brandon
    Phillips, Suzanne
    Miller, Carla
    Gonzalez, Mariann
    Orlowski, Robert Z.
    BLOOD, 2017, 130
  • [8] Lenalidomide after autologous stem cell transplantation in multiple myeloma
    Sanchez, A.
    Notario, C.
    Rios, P.
    Brena, J.
    Oliva, A.
    Afonso, V.
    Rios, M.
    Marreno, C.
    Hermandez, N.
    Cabello, A.
    Jover, S.
    Leon, A.
    Trujillo, M.
    Mesa, C.
    Perez, G.
    Herrera, M.
    Garcia-Talavera, J.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S330 - S330
  • [9] Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
    Baertsch, Marc-Andrea
    Mai, Elias K.
    Hielscher, Thomas
    Bertsch, Uta
    Salwender, Hans J.
    Munder, Markus
    Fuhrmann, Stephan
    Duehrsen, Ulrich
    Brossart, Peter
    Neben, Kai
    Schlenzka, Jana
    Kunz, Christina
    Raab, Marc S.
    Hillengass, Jens
    Jauch, Anna
    Seckinger, Anja
    Hose, Dirk
    Luntz, Steffen
    Sonneveld, Pieter
    Lokhorst, Henk
    Martin, Hans
    Goerner, Martin
    Hoffmann, Martin
    Lindemann, Hans-Walter
    Bernhard, Helga
    Blau, Igor W.
    Scheid, Christof
    Besemer, Britta
    Weisel, Katja C.
    Haenel, Mathias
    Duerig, Jan
    Goldschmidt, Hartmut
    BLOOD CANCER JOURNAL, 2021, 11 (01)
  • [10] Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation
    Jones, John R.
    Pawlyn, Charlotte
    Jackson, Graham H.
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (10) : 1137 - 1145
12345